@article{20.500.13003/20643, year = {2024}, month = {6}, url = {https://hdl.handle.net/20.500.13003/20643}, abstract = {Biologic asthma therapies reduce exacerbations and long-term oral corticosteroids (LTOCS) use in randomized controlled trials (RCTs); however, there are limited data on outcomes among patients ineligible for RCTs. Hence, we investigated responsiveness to biologics in a real-world population of adults with severe asthma. Adults in the International Severe Asthma Registry (ISAR) with ≥24 weeks of follow-up were grouped into those who did, or did not, initiate biologics (anti-IgE, anti-IL5/IL5R, anti-IL4/13). Treatment responses were examined across four domains: forced expiratory volume in 1 second (FEV1) increase by ≥100 mL, improved asthma control, annualized exacerbation rate (AER) reduction ≥50%, and any LTOCS dose reduction. Super-response criteria were: FEV1 increase by ≥500 mL, new well-controlled asthma, no exacerbations, and LTOCS cessation or tapering to ≤5 mg/day. 5.3% of ISAR patients met basic RCT inclusion criteria; 2116/8451 started biologics. Biologic initiators had worse baseline impairment than non-initiators, despite having similar biomarker levels. Half or more of initiators had treatment responses: 59% AER reduction, 54% FEV1 increase, 49% improved control, 49% reduced LTOCS, of which 32%, 19%, 30%, and 39%, respectively, were super-responses. Responses/super-responses were more frequent in biologic initiators than in non-initiators; nevertheless, ~40-50% of initiators did not meet response criteria. Most patients with severe asthma are ineligible for RCTs of biologic therapies. Biologics are initiated in patients who have worse baseline impairments than non-initiators despite similar biomarker levels. Although biologic initiators exhibited clinical responses and super-responses in all outcome domains, 40-50% did not meet the response criteria.}, title = {Real-world biologics response and super-response in the International Severe Asthma Registry cohort}, doi = {10.1111/all.16178}, journal = {Allergy}, author = {Denton, Eve and Hew, Mark and Peters, Matthew J and Upham, John W and Bulathsinhala, Lakmini and Tran, Trung N and Martin, Neil and Bergeron, Celine and Al-Ahmad, Mona and Altraja, Alan and Larenas-Linnemann, Désirée and Murray, Ruth and Celis-Preciado, Carlos Andrés and Al-Lehebi, Riyad and Belhassen, Manon and Bhutani, Mohit and Bosnic-Anticevich, Sinthia Z and Bourdin, Arnaud and Brusselle, Guy G. and Busby, John and Canonica, Giorgio Walter and Heffler, Enrico and Chapman, Kenneth R and Charriot, Jérémy and Christoff, George C and Chung, Li Ping and García-Cosío, Borja and Côté, Andréanne and Costello, Richard W. and Cushen, Breda and Fingleton, James and Fonseca, João A and Gibson, Peter G and Heaney, Liam G and Huang, Erick Wan-Chun and Iwanaga, Takashi and Jackson, David J and Koh, Mariko Siyue and Lehtimäki, Lauri and Máspero, Jorge and Mahboub, Bassam and Menzies-Gow, Andrew N and Mitchell, Patrick D and Papadopoulos, Nikolaos G and Papaioannou, Andriana I and Perez-de-Llano, Luis and Perng, Diahn-Warng and Pfeffer, Paul E and Popov, Todor A and Porsbjerg, Celeste M and Rhee, Chin Kook and Roche, Nicolas and Sadatsafavi, Mohsen and Salvi, Sundeep and Schmid, Johannes M. and Sheu, Chau-Chyun and Sirena, Concetta and Torres-Duque, Carlos A and Salameh, Laila and Patel, Pujan H and Ulrik, Charlotte Suppli and Wang, Eileen and Wechsler, Michael E and Price, David B}, }